Researcher.Life Logo

Expert Opinion on Biological Therapy : Impact Factor & More

eISSN: 1744-7682pISSN: 1471-2598

Aims and Scope of Expert Opinion on Biological Therapy

Expert Opinion on Biological Therapy is a monthly peer-reviewed medical journal covering research on all aspects of biological therapy, including gene therapy and gene transfer technologies, therapeutic peptides and proteins, vaccines and antibodies, and cell- and tissue-based therapies. The journal is published by Taylor & Francis and the editor-in-chief is Michael Morse (Duke University Hospital). The journal was established in 2001 and according to the Journal Citation Reports, it has a 2017 impact factor of 3.974. The journal is also indexed in MEDLINE. Less

Key Metrics

CiteScore
7.2
Eigenfactor
0.005 - 0.01
H-Index
96
Impact Factor
< 5
SJR
Q1Pharmacology
SNIP
1.01
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Expert Opinion on Biological Therapy

Expert Opinion on Biological Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher TAYLOR & FRANCIS LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year2001
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Expert Opinion on Biological Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Expert Opinion on Biological Therapy

Reframing guselkumab’s benefit in ulcerative colitis: insights from QUASAR and emerging evidence
  • 27 Nov 2025
  • Expert Opinion on Biological Therapy
Reply to: reframing guselkumab’s benefit in ulcerative colitis: insights from QUASAR and emerging evidence
  • 25 Nov 2025
  • Expert Opinion on Biological Therapy
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis
  • 20 Nov 2025
  • Expert Opinion on Biological Therapy
Ten-year trend of rituximab use for hematological malignancies: a multiregional real-world study using the Italian VALORE distributed database network
  • 8 Nov 2025
  • Expert Opinion on Biological Therapy
Real-world effectiveness and predictors of complete skin clearance (PASI 100) with anti-IL-23 monoclonal antibodies in moderate-to-severe psoriasis: a retrospective cohort study
  • 6 Nov 2025
  • Expert Opinion on Biological Therapy
Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach
  • 5 Nov 2025
  • Expert Opinion on Biological Therapy
Reframing guselkumab’s benefit in ulcerative colitis: insights from QUASAR and emerging evidence
  • 27 Nov 2025
  • Expert Opinion on Biological Therapy
Reply to: reframing guselkumab’s benefit in ulcerative colitis: insights from QUASAR and emerging evidence
  • 25 Nov 2025
  • Expert Opinion on Biological Therapy
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis
  • 20 Nov 2025
  • Expert Opinion on Biological Therapy
Ten-year trend of rituximab use for hematological malignancies: a multiregional real-world study using the Italian VALORE distributed database network
  • 8 Nov 2025
  • Expert Opinion on Biological Therapy
Real-world effectiveness and predictors of complete skin clearance (PASI 100) with anti-IL-23 monoclonal antibodies in moderate-to-severe psoriasis: a retrospective cohort study
  • 6 Nov 2025
  • Expert Opinion on Biological Therapy
Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach
  • 5 Nov 2025
  • Expert Opinion on Biological Therapy

FAQs on Expert Opinion on Biological Therapy